Zylorion Receives Approval for Phase II Clinical Study for its Proprietary Almond Therapy

Psilotec Health, operating as Zylorion, has announced that it has received approval from the Health Research Ethics Board of Alberta to conduct a phase II clinical study for patients suffering from treatment-resistant depression.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account
Category Press Release
Published in Biospace

Companies Featured

Psilotec Health Solutions
Psilotec aims to produce psilocybin-containing mushrooms and train therapists to treat mental health disorders.

Inline Feedbacks
View all comments